A versatile DNMT and HDAC inhibitor, C02S, was developed to treat breast cancer and has been shown to reverse aberrant methylation and acetylation at the cellular level and to increase the expression of tumour suppressor proteins, ultimately suppressing tumour cell proliferation in vitro and tumour growth in vivo48. The gene discussed is DNMT1; the disease is breast cancer.